Oncobiologics (NASDAQ:OTLK) Issues Earnings Results

Oncobiologics (NASDAQ:OTLK) released its quarterly earnings data on Friday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.97 million.

Here are the key takeaways from Oncobiologics’ conference call:

• FDA approval secured for LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S., positioning Outlook Therapeutics to target the established market for repackaged off-label bevacizumab.
• Management is targeting more than $500 million in peak U.S. annual sales by 2030, with potential upside of nearly $300 million if compounded bevacizumab availability is disrupted. The company expects a first-year U.S. revenue ramp of $50 million-$75 million, accelerating after an anticipated permanent J-code in April 2027.
• The company plans a measured U.S. launch later this year, including approximately 30 customer-facing commercial hires and 20 field reimbursement personnel. It expects LYTENAVA’s wholesale acquisition price to be below $500 per vial and is preparing payer engagement, supply, and coding infrastructure.
• Outlook reported only $11.2 million in cash at June 30, although a subsequent $55 million offering is expected to provide approximately $51.1 million in net proceeds. Quarterly SG&A is expected to roughly double by the end of 2026 and rise another 10% in 2027 to support commercialization.
• European commercialization remains challenging because of reimbursement constraints, pricing pressure, and local compounding practices. Management expects Europe to represent less than one-quarter of the U.S. opportunity by 2030, despite improving unit sales and planned expansion into additional markets.

Oncobiologics Trading Down 14.9%

Oncobiologics stock traded down $0.13 during trading on Friday, hitting $0.76. The company had a trading volume of 104,469,209 shares, compared to its average volume of 13,115,878. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39. The company’s 50 day simple moving average is $1.31 and its 200-day simple moving average is $0.70. The stock has a market cap of $112.39 million, a price-to-earnings ratio of -0.65 and a beta of 0.82.

Insider Activity

In other news, Director Faisal Ghiath Sukhtian bought 95,398 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average cost of $1.05 per share, with a total value of $100,167.90. Following the transaction, the director directly owned 220,972 shares in the company, valued at $232,020.60. The trade was a 75.97% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ghiath M. Sukhtian bought 8,539,709 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was purchased at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the completion of the transaction, the director owned 22,092,068 shares in the company, valued at $13,034,320.12. This represents a 63.01% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 8,664,107 shares of company stock worth $5,162,666. 1.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. AQR Capital Management LLC boosted its position in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on OTLK. Ascendiant Capital Markets lifted their price target on Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. HC Wainwright upped their price objective on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a report on Monday, July 27th. BTIG Research restated a “buy” rating and set a $4.00 price objective on shares of Oncobiologics in a research report on Friday. Wall Street Zen upgraded shares of Oncobiologics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.65.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.